Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
以特征为驱动的米哚妥林再利用，与 MEK1/2 和 KRASG12C 抑制剂联合用于治疗肺癌
期刊:Nature Communications
影响因子:14.7
doi:10.1038/s41467-023-41828-z
Irati Macaya #, Marta Roman #, Connor Welch, Rodrigo Entrialgo-Cadierno, Marina Salmon, Alba Santos, Iker Feliu, Joanna Kovalski, Ines Lopez, Maria Rodriguez-Remirez, Sara Palomino-Echeverria, Shane M Lonfgren, Macarena Ferrero, Silvia Calabuig, Iziar A Ludwig, David Lara-Astiaso, Eloisa Jantus-Lewi
